Literature DB >> 31949929

Interleukin-8 associated with chemosensitivity and poor chemotherapeutic response to gastric cancer.

Sirikan Limpakan Yamada1,2, Pattama Wongsirisin3,4, Supachai Yodkeeree3,4,5, Bandhuphat Chakrabandhu1,2, Wilaiwan Chongruksut1,2, Pornngarm Limtrakul Dejkriengkraikul3,4,5.   

Abstract

BACKGROUND: Gastric cancer (GC) patients have been found to have developed chemotherapy resistance that has resulted in a lowering of their overall survival rates. Interleukin-6 (IL-6) and interleukin-8 (IL-8) could be responsible as the predictive biomarkers in monitoring drug resistance. We have developed a protocol to monitor drug treatment by testing ex vivo chemosensitivity and cytokine levels of primary gastric cultures obtained from endoscopic biopsies.
METHODS: We studied 49 patients with distal GC who underwent primary surgical resection between June 2014 and December 2016 in the northern endemic region of Thailand. The clinical and pathological data of patients were recorded, and the cancer sub-type was classified. The correlation of cytokine IL-6 and IL-8 protein expression levels and chemotherapy sensitivity in primary gastric cultures was investigated. Endoscopic biopsies were collected before and/or after chemotherapy treatment followed by FOLFOXIV regimen (oxaliplatin + 5-FU/leucovorin). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to examine ex vivo chemosensitivity to cisplatin, oxaliplatin, 5-fluorouracil (5-FU) and irinotecan. Enzyme-linked immunosorbent assay (ELISA) was performed to investigate cytokine levels.
RESULTS: Ex vivo drug treatment of 49 primary gastric cultures from naive patients revealed a significant correlation between basal levels of IL-8 and chemosensitivity to cisplatin (P=0.001) and oxaliplatin (P=0.001). IL-8 protein expression levels were significantly decreased in the early phase after cisplatin and oxaliplatin treatments leading to an increase in cell sensitivity to drug treatments. Among 49 patients, 11 patients were classified as partial or poor responders after drug interventions, in which case, second endoscopic biopsies were performed for determination of chemosensitivity and cytokine levels. The results demonstrated significant decreases in sensitivity to cisplatin (P=0.049) and oxaliplatin (P=0.014), meanwhile IL-8 protein expression levels were significantly increased by P=0.0423 in both drug treatments. There was no correlation of IL-6 and drug resistance when treatments of the primary gastric cultures involved each of the four chemotherapeutic drugs (P=0.0663).
CONCLUSIONS: Upregulation of IL-8 after drug intervention might be useful as predictive biomarker in monitoring drug resistance in GC patients; however, this needs to be confirmed among a larger number of patients and with control groups that are properly age-paired. The established primary gastric culture could serve as a valuable tool for chemotherapy screening, while the repeated usage of platinum drugs may result in drug resistance via upregulation of IL-8 levels. 2019 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Advanced gastric cancer (advanced GC); chemosensitivity; interleukin-6 (IL-6); interleukin-8 (IL-8); primary cancer cell

Year:  2019        PMID: 31949929      PMCID: PMC6955000          DOI: 10.21037/jgo.2019.09.02

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  21 in total

Review 1.  Gastric cancer treatment in the world: Germany.

Authors:  Seung-Hun Chon; Felix Berlth; Patrick Sven Plum; Till Herbold; Hakan Alakus; Robert Kleinert; Stefan Paul Moenig; Christiane Josephine Bruns; Arnulf Heinrich Hoelscher; Hans-Joachim Meyer
Journal:  Transl Gastroenterol Hepatol       Date:  2017-05-26

2.  Correlation of Helicobacter pylori and interleukin-8 mRNA expression in high risk gastric cancer population prediction.

Authors:  Wilaiwan Chongruksut; Sirikan Limpakan Yamada; Bandhuphat Chakrabandhu; Chidchanok Ruengorn; Sirisak Nanta
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

3.  The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116.

Authors:  Daiva Dabkeviciene; Violeta Jonusiene; Vilmante Zitkute; Egle Zalyte; Pranas Grigaitis; Vida Kirveliene; Ausra Sasnauskiene
Journal:  Med Oncol       Date:  2015-10-30       Impact factor: 3.064

4.  Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor.

Authors:  Tatsuto Ashizawa; Ryosuke Okada; Yoshiaki Suzuki; Makoto Takagi; Tatsuyuki Yamazaki; Tetsuo Sumi; Toshiaki Aoki; Shinobu Ohnuma; Tatsuya Aoki
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

5.  Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.

Authors:  Seo Young Park; Jiyou Han; Jong Bin Kim; Man-Gil Yang; Yoon Jun Kim; Hee-Joung Lim; Su Yeon An; Jong-Hoon Kim
Journal:  Eur J Cancer       Date:  2013-10-22       Impact factor: 9.162

Review 6.  Cytokine patterns in patients with cancer: a systematic review.

Authors:  Bodo E Lippitz
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

7.  Interleukin-6 promotes carcinogenesis through multiple signal pathways. Comment on: Clinical significance of interleukin-6 gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Jiezhong Chen; Xu-Feng Huang
Journal:  Dig Dis Sci       Date:  2009-04-01       Impact factor: 3.199

Review 8.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

9.  Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).

Authors:  Wasaburo Koizumi; Yeul Hong Kim; Masashi Fujii; Hoon Kyo Kim; Hiroshi Imamura; Kyung Hee Lee; Takuo Hara; Hyun Cheol Chung; Taroh Satoh; Jae Yong Cho; Hisashi Hosaka; Akihito Tsuji; Akinori Takagane; Mikito Inokuchi; Kazuaki Tanabe; Tatsuya Okuno; Mariko Ogura; Kazuhiro Yoshida; Masahiro Takeuchi; Toshifusa Nakajima
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-24       Impact factor: 4.553

10.  Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway.

Authors:  Vicenç Ruiz de Porras; Sara Bystrup; Anna Martínez-Cardús; Raquel Pluvinet; Lauro Sumoy; Lynne Howells; Mark I James; Chinenye Iwuji; José Luis Manzano; Laura Layos; Cristina Bugés; Albert Abad; Eva Martínez-Balibrea
Journal:  Sci Rep       Date:  2016-04-19       Impact factor: 4.379

View more
  2 in total

Review 1.  Targeting mitochondria as a therapeutic anti-gastric cancer approach.

Authors:  Peticha Tanprasert; Sirikan Limpakan Yamada; Siriporn C Chattipakorn; Nipon Chattipakorn; Krekwit Shinlapawittayatorn
Journal:  Apoptosis       Date:  2022-01-28       Impact factor: 4.677

Review 2.  Role of Interleukins and New Perspectives in Mechanisms of Resistance to Chemotherapy in Gastric Cancer.

Authors:  Marlena Janiczek-Polewska; Łukasz Szylberg; Julian Malicki; Andrzej Marszałek
Journal:  Biomedicines       Date:  2022-07-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.